Provectus Biopharmaceuticals, Inc. (PVCT)
OTCMKTS
· Delayed Price · Currency is USD
0.0865
+0.0014 (1.67%)
Aug 15, 2025, 3:53 PM EDT
PVCT Revenue
Provectus Biopharmaceuticals had revenue of $57.48K in the quarter ending June 30, 2025, a decrease of -77.46%. This brings the company's revenue in the last twelve months to $460.19K, down -32.71% year-over-year. In the year 2024, Provectus Biopharmaceuticals had annual revenue of $617.14K with 10.66% growth.
Revenue (ttm)
460.19K
Revenue Growth
-32.71%
P/S Ratio
79.02
Revenue / Employee
76.70K
Employees
6
Market Cap
36.36M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
BioStem Technologies | 332.45M |
Provectus Biopharmaceuticals News
- 7 weeks ago - Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer - GlobeNewsWire
- 2 months ago - Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders - GlobeNewsWire
- 7 months ago - Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs - GlobeNewsWire
- 9 months ago - Provectus Biopharmaceuticals, Inc. (PVCT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 9 months ago - Provectus Biopharmaceuticals GAAP EPS of $0.00, revenue of $0.11M - Seeking Alpha
- 11 months ago - Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call - GlobeNewsWire
- 1 year ago - Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines - GlobeNewsWire
- 1 year ago - Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting - GlobeNewsWire